Printed from Voxsanity (voxsanity.com.au) — NCT07178678 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Alzheimers Disease
Phase 2 Alzheimer's Disease Trial, Not Yet Recruiting
NCT07178678
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 50 or older, reflecting the age group most likely to have Alzheimer's Disease as the cause of their dementia.
- People who score between 3 and 5 (inclusive) on the Global Deterioration Scale, a tool doctors use to measure the stage of memory and thinking decline.
- People who score between 1 and 2 on the Clinical Dementia Rating – Global Score at the screening visit (confirm with trial site).
- People whose airways are clear and unobstructed.
- People (or their caregiver, if the person themselves cannot) who are willing to give written consent to take part in the study.
- People who have a caregiver who is physically and mentally able to assist with the study requirements.
- People who score between 14 and 26 (inclusive) on the Mini-Mental State Examination, a standard test of memory and thinking, at the screening visit.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with a clear mental disability or other limitation that would prevent the person or their caregiver from completing the study assessments.
- People with neurological symptoms or signs that suggest their dementia may be caused by something other than Alzheimer's Disease.
- People who have had a head injury or brain surgery recently.
- People with known blood clotting disorders.
- People currently using blood-thinning medications such as warfarin, heparin, or a newer anticoagulant (NOAC).
- People who have another serious illness or condition that may cause significant disability, including cancer, certain heart infections, blood disorders, severely reduced kidney function, high potassium levels in the blood, or chronic or severe liver, kidney, or heart disease.
- People with a known history of allergic reaction to a medicine called rhEPO (recombinant human erythropoietin).
- People with a known allergy to any ingredient in the study product.
- People who have nasal irritation such as sneezing or a runny nose before starting treatment.
- People who are having an asthma attack at the start of treatment.
- People taking medications for dementia (AChE inhibitors or Memantine) whose dose has not been stable for at least 12 weeks before the screening visit.
- People taking medications that affect mood, thinking, or behaviour in a way that could interfere with trial results or cognitive testing.
- People with a history of alcoholism or dependence on drugs.
- People with chronic rhinosinusitis (long-term inflammation of the sinuses and nasal passages).
- People with a history of abnormal nasal or sinus symptoms.
- People who have had a skull fracture in the past or have a nasal abnormality such as a deviated septum or nasal defect.
- People who have had a nasal fracture within the last 2 months.
- People who have previously had surgery on the nose or sinuses, including rhinoplasty (nose reshaping surgery).
- People with a known bleeding problem, including low platelet levels (thrombocytopenia) or recurring nosebleeds (more than 3 times per year).
- People with acute (sudden or current) inflammation inside the nose.
- People born with a craniofacial disorder (a condition affecting the structure of the skull or face).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
University of Saskatchewan
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
1 March 2030
Where this trial is recruiting
🇨🇦 Canada
Primary endpoints
Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog13)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.